Figure 8. TAT-APPsweBBP markedly reduces β-amyloid deposits.
(A) TAT-APPsweBBP markedly reduced β-amyloid plaques in retrosplenial cortex (RSC), entorhinal cortex (EC) and hippocampus (H) regions of 5XFAD mouse brains, as determined by immunohistochemical staining with anti-Aβ16−26 antibody (4G8). (B) Percentage of 4G8 immunoreactive areas in regions of interest (RSC, EC and H regions) was quantified by image analysis for each treatment group. Data are represented as mean ± SD (n = 10, 5 female/5 male). A t test for independent samples revealed significant differences between TAT-APPsweBBP and TAT peptide treatment groups (**P < 0.01), but no significant difference between TAT peptide and PBS groups.